Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women. Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.
- Mechanism
- Curator reviewed · 3 references
Medrogestone is a progestogen, thus its action is done under the same profile. These type of molecules are steroid hormones that bind and activate the progesterone receptor. Its action may involve the suppression of gonadotropic hormones from the anterior portion of the pituitary gland and secondary suppression of testosterone. Medrogestone presents structural similarities to testosterone which allows it to compete for the androgen-receptor-protein receptor sites in prostatic cells. Administration of medrogestone diminishes the response to endogenous hormones in tumor cells due to a reduction in hormone steroid receptors; this effect will translate into cytotoxic or antiproliferative effects.
- Primary indication
- Medrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.Curator reviewed · 1 structured indication
- Formula / weight
- C23H32O2 · 340.507 g/mol (avg)
- First approval
- Canada, 1969
- Code names
- AY-13615 · AY-13615S · AY-62022 · NSC-123018
Resolves to
HCFSGRMEEXUOSS-JXEXPEPMSA-NSMILES[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12CWhat you can answer from here — as of January 17, 2025
Which drugs share a target with Medrogestone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account